lung cancer
Conditions
Interventions
Gold Standard:gene mutaiton detection using tumor tissue
detection 
using 
blood 
Sponsors
Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18-85 years; 2) Chest CT indicated that pulmonary lesions had the characteristics of malignant lesions; 3) Did not receive any anti-tumor intervention therapy, including radiotherapy, chemotherapy, immunotherapy, etc.Does not include antibiotic treatment; 4) Non-small cell lung cancer can be confirmed by puncture or surgery; 5) Be willing to provide blood samples and tissue samples for this clinical study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) There are other malignant tumors at the same time, including adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection; 2) The investigator determined that the subjects had other serious non-tumor diseases that might affect follow-up and short-term survival; 3) Subjects who have previously received anti-tumor therapy such as surgery, chemotherapy, targeted or immunotherapy; 4) Clinically definite active infection, including but not limited to pneumonia, tuberculosis, cryptococcosis and other infections; 5) Subjects who cannot obtain the results of EGFR, KRAS and P53 mutations in tissues or red blood cells due to unqualified quality inspection of samples; 6) Subjects who cannot receive any anti-tumor intervention therapy; 7) Female subjects during pregnancy or lactation; 8) Other researchers think it is not suitable to be included in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EGFR mutation;KRAS mutation;P53 mutation; | — |
Countries
China
Contacts
Public ContactQihan Chen
Outcome results
None listed